Antibodies News and Research

RSS

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021

New study will help design better antibodies for potential treatments

Scientists are harnessing hard X-rays in the fight against cancer. A team of researchers, in conjunction with the U.S. Department of Energy's (DOE) Argonne National Laboratory, has used ultrabright X-ray light to determine how specific types of antibodies can tell the difference between different forms of a cancer-linked molecule.

3 Jun 2021

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows.

2 Jun 2021

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

2 Jun 2021

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

A new bioRxiv* preprint reports on the successful use of a protocol to expand SARS-CoV-2-reactive T-cells a thousand-fold.

2 Jun 2021

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

A recent study conducted by a team of scientists in the Netherlands has revealed that while severely affected hospitalized COVID-19 patients and vaccinated individuals are capable of neutralizing the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2, a significant proportion of non-hospitalized patients with less severe COVID-19 remain susceptible to these viral variants.

2 Jun 2021

Can immunity form and interaction with seasonal coronaviruses influence SARS-CoV-2 epidemiology?

A new study hypothesizes that cross-protection from seasonal epidemics of HCoVs could not only affect SARS-CoV-2 transmission but also protect children from the disease.

2 Jun 2021

How antibody production in the lungs can determine severe respiratory infections

Recent findings describe how the presence of certain antibodies within the lungs can induce an immune response to minimize the effects of these infections.

2 Jun 2021

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.

2 Jun 2021

Novel antibody engineering approach

Scientists from the Johns Hopkins University School of Medicine, USA, have recently developed an Antibody Display technology by grafting the second extracellular domain of tetraspanin12 (Tspan12EC2) and the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein on the heavy chain complementarity-determining region 3 (CDR3).

2 Jun 2021

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

An international team of scientists has identified a human molecule — biliverdin — as a potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target. The binding of the heme metabolite to the N-terminal domain of SARS-CoV-2 is associated with the virus’s ability to dodge the immune system by suppressing antibody binding to the spike protein.

2 Jun 2021

Direct action of SARS-CoV-2 on organs may lead to exacerbated inflammatory response in pediatric patients

Besides common symptoms such as fever, cough and respiratory distress, some children have an atypical form of COVID-19 known as multisystem inflammatory syndrome in children (MIS-C), characterized by persistent fever and inflammation of several organs, such as the heart and intestines, as well as the lungs to a lesser extent.

1 Jun 2021

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

1 Jun 2021

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Researchers from Ontario, Canada, recently conducted a prospective observational study to determine the SARS-CoV-2 antibody response in chronic hemodialysis patients following one vs. two doses of the BNT162b2 COVID-19 vaccine. The results were compared to health care worker controls and convalescent serum.

1 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Although Peru is one of the countries most affected by the pandemic, no studies had been conducted to investigate SARS-CoV-2 seroprevalence among domestic cats. Recently, researchers from Peru demonstrated the presence of neutralizing antibodies for the receptor binding-domain (RBD) of the SARS-CoV-2 spike protein in cats in Lima, Peru. The owners of the cats in the study had confirmed SARS-CoV-2 infection.

1 Jun 2021

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

Researchers from the US tested the prophylactic potential of a combination of 2 mAbs administered 3 or 75 days before respiratory challenge in rhesus macaques. They used the rhesus macaque model to test the added benefit of combinatory parenteral administration of 2 high-affinity anti-SARS-CoV-2 mAbs - C144-LS and C135-LS. These mAbs were developed to neutralize the virus and tweaked to improve their pharmacokinetics.

1 Jun 2021

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

A new discovery in Ewing sarcoma, an aggressive and often fatal childhood cancer, has uncovered the potential to prevent cancer cells from spreading beyond their primary tumor site.

1 Jun 2021

Researchers identify common epitopes across SARS-CoV-2 viral variants

While several COVID-19 vaccine candidates have been developed and deployed to arrest the spread of SARS-CoV-2, concern among scientists and public health authorities is mounting over the immunity escape potential of emerging viral variants. To address this problem, a group of scientists in Germany has undertaken research to identify molecular targets across viral variants to aid in the development of second and third-generation vaccines and novel therapeutics.

1 Jun 2021

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a coronavirus disease (COVID-19) treatment.

1 Jun 2021

Antibodies News and Research

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

New study will help design better antibodies for potential treatments

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Can immunity form and interaction with seasonal coronaviruses influence SARS-CoV-2 epidemiology?

How antibody production in the lungs can determine severe respiratory infections

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Novel antibody engineering approach

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

Direct action of SARS-CoV-2 on organs may lead to exacerbated inflammatory response in pediatric patients

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

Study confirms poor immunogenicity in hemodialysis patients receiving single dose BNT162b2 vaccine

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

Compelling evidence of SARS-CoV-2 exposure and neutralizing antibodies in domestic cats in Peru

Antibody cocktail effectively inhibits SARS-CoV-2 in the rhesus macaque model

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

Researchers identify common epitopes across SARS-CoV-2 viral variants

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News